These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37047086)

  • 61. Predictors of Response to Biologics in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Cohort Study.
    Schwarz CW; Loft N; Rasmussen MK; Nissen CV; Dam TN; Ajgeiy KK; Egeberg A; Skov L
    Acta Derm Venereol; 2021 Oct; 101(10):adv00579. PubMed ID: 34642768
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Ex vivo inhibited cytokine profiling may explain inferior treatment response to golimumab after adalimumab failure in rheumatoid arthritis.
    Tweehuysen L; Schraa K; Netea MG; van den Hoogen FHJ; Joosten LAB; den Broeder AA
    Clin Exp Rheumatol; 2018; 36(1):140-143. PubMed ID: 29148425
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Biologics switch in psoriasis.
    Wang TS; Tsai TF
    Immunotherapy; 2019 Apr; 11(6):531-541. PubMed ID: 31135243
    [No Abstract]   [Full Text] [Related]  

  • 65. Efficacy comparison of ustekinumab between anti-tumor necrosis factor-α drug-naïve and anti-tumor necrosis factor-α drug-resistant Japanese psoriasis cases.
    Takahashi N; Noda S; Taniguchi T; Adachi M
    Int J Dermatol; 2015 Oct; 54(10):1194-8. PubMed ID: 26016819
    [TBL] [Abstract][Full Text] [Related]  

  • 66. TNFα and IL-17A are differentially expressed in psoriasis-like vs eczema-like drug reactions to TNFα antagonists.
    Deubelbeiss C; Kolios AGA; Anzengruber F; French LE; Yawalkar N; Kempf W; Kerl K; Meier B; Navarini AA
    J Cutan Pathol; 2018 Jan; 45(1):23-28. PubMed ID: 29023827
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Pathway Analysis of Skin from Psoriasis Patients after Adalimumab Treatment Reveals New Early Events in the Anti-Inflammatory Mechanism of Anti-TNF-α.
    Langkilde A; Olsen LC; Sætrom P; Drabløs F; Besenbacher S; Raaby L; Johansen C; Iversen L
    PLoS One; 2016; 11(12):e0167437. PubMed ID: 28005985
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Multiple Cytokine Analysis of Th1/Th2/Th9/Th17/Th22/Treg Cytokine Pathway for Individual Immune Profile Assessment in Patients with Psoriasis.
    Michalak-Stoma A; Bartosińska J; Raczkiewicz D; Kowal M; Kozak J; Gujski M; Krasowska D; Chodorowska G
    Med Sci Monit; 2022 Nov; 28():e938277. PubMed ID: 36419330
    [TBL] [Abstract][Full Text] [Related]  

  • 69. TNF-α in a molecularly targeted therapy of psoriasis and psoriatic arthritis.
    Wcisło-Dziadecka D; Zbiciak-Nylec M; Brzezińska-Wcisło L; Mazurek U
    Postgrad Med J; 2016 Mar; 92(1085):172-8. PubMed ID: 26719452
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy.
    Chen DY; Chen YM; Chen HH; Hsieh CW; Lin CC; Lan JL
    Arthritis Res Ther; 2011 Jul; 13(4):R126. PubMed ID: 21801431
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Japanese guidance for use of biologics for psoriasis (the 2019 version).
    Saeki H; Terui T; Morita A; Sano S; Imafuku S; Asahina A; Komine M; Etoh T; Igarashi A; Torii H; Abe M; Nakagawa H; Watanabe A; Yotsuyanagi H; Ohtsuki M;
    J Dermatol; 2020 Mar; 47(3):201-222. PubMed ID: 31916326
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort.
    Van Muijen ME; Thomas SE; Groenewoud HMM; Otero ME; Ossenkoppele PM; Njoo MD; Dodemont SRP; Kop EN; Berends MAM; Koetsier MIA; Mommers JM; Körver JEM; Tupker RA; De Bruin-Weller MS; Weppner-Parren LJMT; Peters B; Kleinpenning MM; Kuijpers ALA; Arnold WP; Van Lümig PPM; Van den Reek JMPA; De Jong EMGJ
    Acta Derm Venereol; 2022 May; 102():adv00712. PubMed ID: 35356990
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cytokine Signatures in Psoriatic Arthritis Patients Indicate Different Phenotypic Traits Comparing Responders and Non-Responders of IL-17A and TNFα Inhibitors.
    Skougaard M; Ditlev SB; Søndergaard MF; Kristensen LE
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047315
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Evaluation of Psoriasis Area and Severity Index Thresholds as Proxies for Systemic Inflammation on an Individual Patient Level.
    Hoffmann JHO; Enk AH
    Dermatology; 2022; 238(4):609-614. PubMed ID: 34852349
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Secukinumab for patients failing previous tumour necrosis factor-α inhibitor therapy: results of a randomized open-label study (SIGNATURE).
    Warren RB; Barker JNWB; Finlay AY; Burden AD; Kirby B; Armendariz Y; Williams R; Hatchard C; Khare S; Griffiths CEM
    Br J Dermatol; 2020 Jul; 183(1):60-70. PubMed ID: 31628677
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Dysregulation of innate immunity in ulcerative colitis patients who fail anti-tumor necrosis factor therapy.
    Baird AC; Mallon D; Radford-Smith G; Boyer J; Piche T; Prescott SL; Lawrance IC; Tulic MK
    World J Gastroenterol; 2016 Nov; 22(41):9104-9116. PubMed ID: 27895398
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Therapeutic drug monitoring of patients with psoriasis during tumour necrosis factor (TNF)-α antagonist treatment using a novel interleukin-8 reporter cell line.
    Kimura Y; Shimada-Omori R; Takahashi T; Tsuchiyama K; Kusakari Y; Yamasaki K; Nishikawa R; Nishigori C; Aiba S
    Br J Dermatol; 2016 Nov; 175(5):979-987. PubMed ID: 27155194
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Comparison of serum NO, TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus.
    Doganay S; Evereklioglu C; Er H; Türköz Y; Sevinç A; Mehmet N; Savli H
    Eye (Lond); 2002 Mar; 16(2):163-70. PubMed ID: 11988817
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis.
    Li X; Andersen KM; Chang HY; Curtis JR; Alexander GC
    Ann Rheum Dis; 2020 Feb; 79(2):285-291. PubMed ID: 31672774
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Treatment with TNF-α inhibitor rectifies M1 macrophage polarization from blood CD14+ monocytes in patients with psoriasis independent of STAT1 and IRF-1 activation.
    Lin SH; Chuang HY; Ho JC; Lee CH; Hsiao CC
    J Dermatol Sci; 2018 Sep; 91(3):276-284. PubMed ID: 29914850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.